F2G is a recipient of the 2019 EIB Innovation Award

The Award is in recognition of F2G’s dedication to the development of novel therapies to treat life-threatening invasive fungal infections in an area of a high unmet medical need. In November 2018 F2G Biotech GmbH Austria received a €24M venture loan from the EIB’s InnovFin Infectious Diseases Finance Facility (IDFF). The EIB is one of the largest venture debt providers in Europe and reviews more than 2000 financing requests and conducts more than 70 due diligences per year.



The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.